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ABSTRACT
Transient bacteraemia is a known risk factor following oral surgery and invasive dental procedures in patients with altered 
immune system response and those with a susceptible site of infection (patients with heart valve prostheses or recent 
joint replacements, etc.) The most commonly isolated aerobic bacteria in postoperative bacteraemia are Streptococcus 
Viridans. However, other periodontal pathogenic anaerobic bacteria are found in up to 64% in blood cultures (mixed 
bacteria or anaerobic bacteria alone). Dental pathogenic bacteria do not appear to be covered by standard amoxicillin 
or clindamycin prophylactic regimens. This is partly due to the fact that these anaerobic bacteria often produce beta 
lactamase and also in view of results of antimicrobial sensitivity tests observed in recent studies. 
A personal history of exposure to dental pathogenic bacteria may have an impact on the patient’s global health, not 
only because of classical local or systemic infectious complications, but also because dental pathogenic bacteria have 
been found in atheromatous plaques in coronary and carotid arteries. This finding, along with epidemiological data, 
suggests that such bacteria may contribute to the progression of vascular arteriosclerotic lesions and the occurrence of 
cardiovascular and/or cerebrovascular accidents, although the pathogenic mechanisms involved are not yet well known. 
Taking these facts into consideration, and in view of antimicrobial sensitivity data available at present, we believe that 
the use of amoxicillin/clavulanic acid is the most appropriate option for prophylaxis of all infectious risks associated with 
bacteraemia of oral origin, due to its broader cover of dental pathogenic bacteria and its pharmacokinetic profile. 
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RESUMEN
Tras la cirugía oral y los procedimientos odontológicos invasivos, la bacteriemia transitoria es un factor de riesgo cono-
cido para los pacientes que sufren alteraciones del sistema inmune y para aquellos que presentan focalidad susceptible 
(pacientes con prótesis valvulares cardiacas o prótesis articulares recientes, entre otros). Los Streptococcus viridans 
son las bacterias aerobias aisladas con mayor frecuencia en las bacteriemias postquirúrgicas orales; no obstante otras 
bacterias odontopatógenas anaerobias se encuentran por hemocultivo hasta en el 64% de los casos (tratándose en estos 
casos de bacteriemias mixtas o exclusivamente anaerobias). Las bacterias odontopatógenas no parecen bien cubiertas 
con el régimen profiláctico estándar de amoxicilina o clindamicina, debido, entre otras causas, a la frecuente produc-
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1. ORAL MICROBIOTA AND DENTAL PATHO-
GENIC FLORA 
The mouth is one of the areas of our body with the greatest 
microbial population and variety. Different ecosystems can 
be found in the mouth, where over 200 different aerobic and 
anaerobic bacterial species live. (1) Oral bacteria (dental 
or commensal pathogens) and their products (toxins) may 
move from this primary location to other neighbouring 
or distant locations. Invasive dental procedures and oral 
surgery favour bacterial dissemination, especially into the 
bloodstream, causing transient bacteraemia.
Transient bacteraemia is unavoidable, but its severity (bac-
terial load), duration (time in which bacteria remain in 
the bloodstream), type of bacteria in the blood (aerobic, 
anaerobic or mixed) and the patient’s predisposition (un-
derlying diseases, susceptible site of infection, etc.), all play 
a significant role in the onset of possible complications. 
Bacteraemia, initially considering mono-microbial bacte-
raemia, is caused by contamination/infection of the normal 
oral and dental pathogenic microbiota during the surgical 
procedure. Since the thirties, we have known that 75% of 
patients with caries, gingivitis and periodontitis will have 
positive Streptococcus blood cultures following dental pro-
cedures, in comparison with 30% in healthy subjects. (2, 3) 
Predominant organisms are Streptococcus from the viridans 
group (4), Staphylococcus spp and, in 4-7% of cases, gram-
negative HACEK bacilli (Haemophilus, Actinobacillus, 
Cardiobacterium, Eikenella, Kingella), several of which are 
considered as dental pathogens. (5) We should not neglect 
the existence of mixed (aerobic/anaerobic) bacteraemia, or 
anaerobic bacteraemia alone (Eubacterium, Peptostreptococ-
cus, Propionibacterium, Lactobacillus), which are detected in 
a significantly high percentage of cases when an appropriate 
microbiological method is used (oxygen-free blood cultures 
for anaerobic recovery). (6-8)
 
2.  BACTERAEMIA AND ITS RISKS
The following questions arise when discussing bacteraemia: 
• How and when does it occur? The frequency of bacteraemia 
varies significantly from one study to another, ranging from 
0 to 88% depending on procedures analysed. Thus, it has 
been observed more frequently in invasive oral procedures 
with a higher level of bleeding, such as tooth extractions and 
periodontal surgery. (3-9) However, transient bacteraemia 
has also been observed following tooth brushing, chewing 
and cleaning with dental floss, although there is probably a 
lower bacterial load and shorter-lived bacteraemia in these 
cases, with less consequences for the patient than those that 
arise following invasive procedures. 
• What is the inoculum or bacterial load? The number of 
bacteria in the blood is unknown, since a laborious micro-
biological analysis (quantitative blood cultures) is required to 
assess this. However, we can presume that the bacterial load 
is greater and probably more persistent in invasive processes 
and in patients who present periodontal inflammation. 
• What type of bacteria is involved? Aerobic and anaerobic. 
Lockhart PB et al (9) observed bacteraemia in 84% of chil-
dren undergoing dental procedures and identified 29 different 
species of micro-organisms in blood cultures performed. 
Rajasuo A et al (7) observed transient bacteraemia in 88% 
of patients undergoing tooth extraction (50% within the first 
minute following incision), 74% of which were anaerobic bac-
teria (Prevotella, Eubacterium and Peptostreptococcus). Otten 
et al (8) observed bacteraemia following tooth extraction in 
74% of patients studied, 64.2% of which were mixed bacteria 
(aerobic/anaerobic), isolating S. viridans in 50% of cases. 
However, in 35.8% of these cases anaerobic bacteria alone 
were found. What effects might these anaerobic bacteria have 
on a susceptible patient? We will return to this subject later. 
ción de betalactamasas por dichas bacterias anaerobias y a los resultados de las pruebas de sensibilidad antimicrobiana 
observados en estudios recientes. 
La historia personal de exposición a bacterias odontopatógenas puede repercutir en la salud global del individuo, no 
sólo por las complicaciones infecciosas clásicas: locales o sistémicas, sino por el hecho de haber sido encontradas bacte-
rias odontopatógenas en placas de ateroma de arterias coronarias y carótidas; sugiriendose con este hallazgo, y por los 
datos epidemiológicos, que puedan contribuir (por mecanismos patogénicos aún no bien conocidos) a la progresión de 
lesiones vasculares  arterioescleróticas y a la aparición de accidentes cardiovasculares y/o cerebrovasculares. Tomando en 
consideración estos hechos y los datos de sensibilidad antimicrobiana disponibles, el empleo de amoxicilina/clavulánico 
nos parece la opción más adecuada como profilaxis de todos los riesgos infecciosos asociados con la bacteriemia de 
origen oral, por su mayor cobertura frente a las bacterias odontopatógenas y su mejor perfil farmacocinético.
Palabras clave: Profilaxis, amoxicilina/clavulánico, cirugía oral, procedimientos odontológicos.
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• How long does the bacteraemia last? Bacteraemia peaks 
during the first two minutes following tooth extraction or 
invasive dental procedure, and falls in time. However, oral 
bacteria have been found on blood culture after 1 to 45 
minute periods, following tooth extraction. (9) 
• What future awaits these bacteria in the bloodstream? In 
theory a healthy immune system is capable of eradicating 
bacteria from the blood stream in just a few minutes. 
However, dental pathogenic bacteria have been found in 
atheromatous plaques in carotid and coronary arteries, 
and therefore there is some degree of uncertainty regarding 
their possible pathogenic role, either directly, or indirectly 
(through inflammation) in cardiovascular disease. (10,11)
• Are there susceptible sites in patients? Yes/no. Short, medium 
and long-term risks vary according to these circumstances. 
Patients who are more susceptible to infections following 
bacteraemia are those who have endocardial risks, bone 
prostheses and joint replacements. (12) But in what other 
circumstances does bacteraemia imply a risk? Has the patient 
got incipient, silent vascular arteriosclerotic lesions in caro-
tid or coronary arteries? Are these lesions susceptible sites 
for the growth of bacterial colonies resulting from dental 
pathogenic bacteria in the bloodstream? What pathogenic 
role might oral bacteria play in cardiovascular disease? 
Recent studies using PCR techniques on samples obtained 
from carotid endarterectomy have detected periodontal 
pathogenic bacteria in atheromatous plaques in severely 
damaged vessel walls. (13, 14) Furthermore, other authors 
have related periodontal inflammation with thickening of 
carotid artery walls. (10) In vitro studies have observed that 
Streptococcus viridans and dental pathogenic bacteria such 
as P. gingivalis, are capable of inducing platelet aggregation 
and hypercoagulability. (15,16) Song H et al (17) observed 
that haemagglutinin (HagB), present in the gram-negative 
anaerobic bacteria P. gingivalis, plays a significant role in the 
capacity of this periodontal pathogenic bacteria to adhere 
to human coronary artery endothelial cells. Li L et al (18) 
investigated the effect of repeated intravenous inoculation of 
P. gingivalis in an animal model. Their results indicate that 
this dental pathogenic bacterium is capable of accelerating the 
progression of atheromatous plaques. Coinciding with these 
results, Brodala N et al (19) proceeded to administer repeated 
intravenous injections of P. gingivalis in experimentation 
animals (pigs) and then analysed their carotid and coronary 
arteries. The authors observed that recurrent bacteraemia 
induced arteriosclerotic lesions in normocholesterolaemic 
animals and increased lesions in hypercholesteraemic animals. 
P. gingivalis was detected using PCR in 94% of the arteries of 
the inoculated animals, but not in the control group. In the 
light of these results, is there a causal relationship between 
these bacteria and the evolution of atheromatous plaques, 
in the formation of thrombi in pre-existing arterial plaques, 
or in bringing on cardiovascular accidents in human beings? 
Is this all an insignificant, coincidental finding? Or are we 
missing something?
• Are there any other underlying circumstances that predispose 
a patient to suffering an infectious complication following bac-
teraemia? The following patients are particularly susceptible 
to suffering local and systemic infections: immunocompro-
mised patients, cancer patients, patients with congenital or 
acquired immunodepression (e.g. lupus erythematosus), 
patients with drug-induced immunodepression (steroid 
therapy, chemotherapy), recent recipients of transplants, 
grafts or other causes, patients with infectious immunode-
pression (acquired immunodeficiency syndrome), patients 
with metabolic disorders (diabetes), splenectomies, and with 
kidney or liver failure. (12, 20, 21) 
• Can bacteraemia be avoided? No, but its negative impact 
on patients’ health can be reduced. Lockhart PB et al (9) 
studied the impact of amoxicillin prophylaxis on the inci-
dence, nature and duration of bacteraemia in 100 children 
undergoing tooth extraction and other dental procedures. 
They observed that the incidence of bacteraemia (detecta-
ble on blood culture) was lower in the group that received 
prophylaxis (33% incidence) in comparison with the placebo 
group (84%). They also observed that in the placebo group 
the bacteraemia lasted longer (in some cases up to 30 or 
45 minutes after tooth extraction), whereas in the group 
that received prophylaxis, no bacteraemia was found after 
15 minutes following the intervention. Anaerobic bacteria 
were the most persistent bacteria in the blood. Would it be 
a good idea to consider early eradication of bacteraemia, 
especially in patients who are more susceptible to suffering 
infectious complications? 
• What negative repercussions does bacteraemia have on a 
patient on a short and medium term? In patients with a sus-
ceptible site of infection, such as those who have a mitral 
valve prosthesis and are to undergo oral surgery, bacteria in 
the bloodstream could colonise the valve and/or perivalvular 
tissue, causing infective endocarditis weeks or months after 
surgery. (5,12,22) To reduce the risk of infection, patients 
with a susceptible site of infection (with cardiopathy, recent 
joint replacements, etc.) who are to undergo any invasive 
oral procedure, should be given systemic pre-operative 
antimicrobial prophylaxis. (12, 22,23)
• Are there any prophylaxis regimens that are used to prevent 
infective endocarditis? Although action protocols have been 
widely diffused in scientific journals, in the academic and pro-
fessional media, there is a serious concern regarding the lack of 
information and application of prophylaxis regimens amongst 
health professionals. Thus, Tomás I et al (24) conducted a survey 
amongst 400 Spanish dentists selected at random in 2004, and 
observed that 45% of dentists did not recommend any pro-
phylactic regimen in patients at risk (valve prosthesis carriers) 
prior to surgery. Of the dentists who recommended prophylaxis, 
30% did so correctly for patients who were not allergic to beta 
lactamics and 28.3% did so correctly for those who were aller-
gic to penicillin. The authors were concerned by these results. 
Clearly, there is still much ground to be covered. 
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• What long-term repercussion might there be from exposure 
to dental pathogenic bacteria? The micro-organisms and 
their products (toxins) that are present in the mouth can 
reach any part of the body through the blood. Geerts SO 
et al (25) observed that endotoxaemia could be induced 
simply by chewing, and the risk was greater in patients 
with periodontal disease. Forner L et al (26) observed that 
there was a higher level of bacteraemia following scaling in 
patients with periodontitis than in that observed in patients 
with gingivitis and in healthy subjects. Epidemiological data 
suggest that the infection that is present in the periodontal 
tissues may spread into the bloodstream and contribute 
towards arteriosclerotic progression. Different authors who 
have conducted studies using rigorous methodologies have 
found that there is an association between periodontitis 
and cardiovascular disease, regardless of other factors. (11) 
However, not all studies have established this positive asso-
ciation. (27) The discrepancy continues, since the pathogenic 
mechanism is unknown and the causal relationship remains 
unclear. However, it is possible that a patient’s exposure to 
dental pathogenic bacteria contributes towards the onset 
of cardiovascular and cerebrovascular accidents, at least 
as a risk factor. If  this situation is confirmed, how should 
we approach bacteraemia of oral origin in medical practice 
and dentistry? In periodontal disease, it can be observed 
that the host shows a systemic inflammatory response, with 
elevation of C-reactive protein and other reactants during 
the acute phase, and this may contribute, in part, to these 
patients’ higher risk of cardiovascular disease. On the same 
line, some authors have observed that periodontal treatment 
with antimicrobials reduces C-reactive protein and tumour 
necrosis factor (TNF-alpha) levels, which may be beneficial 
for patients, since high levels of these factors may be asso-
ciated with an increased risk of developing arteriosclerosis 
in patients with periodontitis. (28) Would it be wise to give 
systemic antibiotics to eradicate dental pathogenic bac-
teria in patients who are particularly susceptible? Should 
antibiotics also be administered as prophylaxis to prevent 
cardiovascular and cerebrovascular accidents in selected 
patients? What global benefits would be obtained? Which 
antibiotics would be the best to cover aerobic and anaero-
bic dental pathogen bacterial flora? What role do dentists 
and maxillofacial surgeons play in public health and health 
prevention issues that are apparently far removed from their 
own professional practice? What implications might there be 
in conserving good mouth and dental health in a person’s 
overall well-being, now and in the future? These questions 
and others arise when discussing this subject, and while 
they are being answered, mistakes are being accounted for 
and the truth is being revealed, we would like to make a few 
comments about the suitability of antibiotic prophylaxis in 
oral surgery. 
3. ANTIBIOTIC PROPHYLAXIS IN ORAL SUR-
GERY
Traditionally prophylaxis has been defined as pre- and 
peri-operative administration of  antibiotics in order to 
prevent local and/or systemic post-operative infection. In 
Altemeier’s classification, oral surgery is often graded as 
class II (clean-contaminated surgery), with a rate of local 
infection of 5 to 15% without antibiotics and <7% with 
antibiotics. (20) 
In oral surgical prophylaxis, the target microbiota differs 
depending whether the intention is to prevent local com-
plications (phlegmon, abscess) or distant infections (en-
docardial infections, bone prostheses, joint replacements) 
in risk patients who require prophylaxis because of their 
underlying condition. In order to prevent local infection, 
target microbiota is usually polymicrobial because many 
species tend to be isolated in pairs (Bacteroides sp. and 
Fusobacterium; Peptostreptococcus sp. and Prevotella sp.; 
Prevotella sp. and Eubacterium sp.), with a marked aero-
bic/anaerobic component (29), and to a much lesser extent 
microaerophilous component, since these infections ori-
ginate from the possible surgical contamination/infection 
from the normal microbiota of the mouth and saliva, and 
from dental pathogens in the periodontal disease, which 
has a very high prevalence in the general population (it is 
estimated that about 50% of adults have gingivitis and 30% 
have periodontitis). (30)
Systemic infections that should be prevented in patients with 
underlying disease are caused by bacteraemia, especially 
following invasive procedures. (12) 
4. ANTIMICROBIAL SPECTRUM
The choice of  the antimicrobial spectrum used for pro-
phylaxis should take the following into consideration: 
bacteria that are normally present in the mouth (potential 
pathogens such as Streptococcus Viridans), aerobic and 
anaerobic bacteria detected in bacteraemia of mouth-dental 
origin, bacteria involved in odontogenous infection, and 
all bacteria involved in local and systemic complications. 
Three types of bacteria should be considered, in view of 
their clinical significance: 
1. Periodontal pathogens that cannot be cultured or are 
difficult to isolate, e.g. Treponemas such as T. denticola (and 
other spirochaeta), which are sensitive to penicillin and pre-
sent aetiopathogenic specificity for severe periodontitis. 
2. Anaerobic gram-negative bacteria such as Prevotella spp 
and Fusobacterium spp (these are the most prevalent anae-
robic bacteria in dental infections such as periodontitis, 
pericoronaritis, periodontal and periapical abscesses). 
Approximately 50% of these bacteria produce inactivant 
enzymes (ß-lactamases). Some of them are also detected 
in mixed bacteraemia.
3. Aerobic gram-positive bacteria such as Streptococcus viri-
dans, responsible for post-operative bacteraemia in oral pro-
cedures and distant complications such as endocarditis. 
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5. CAN INFECTIOUS COMPLICATIONS BE 
AVOIDED BY USING AMOXICILLIN OR CLIN-
DAMYCIN PROPHYLAXIS?
Dental pathogenic bacteria do not show homogeneous 
sensitivity to antibiotics. When selecting an antibiotic, we 
need to refer to the largest, most recent and most reliable 
studies, amongst the little research that has been conduc-
ted in this field. As mentioned earlier, local infections are 
usually polymicrobial and mixed, and they involve bacteria 
from the three above groups. Distant complications, such 
as infective endocarditis, are usually mono-microbial, and 
usually involve gram-positive bacteria such as S. viridans. 
When choosing an antibiotic for prophylactic or therapeutic 
use in dental procedures or oral surgery, the aim should be 
for the antibiotic spectrum of action to cover all three types 
of dental pathogenic bacteria mentioned above. (12) In fact, 
assuming that standard antibiotic prophylaxis is amoxicillin 
or clindamycin, it does not appear that these requirements 
are met for different reasons, in view of the sensitivity pre-
sented by dental pathogenic micro-organisms as observed in 
recent studies. (31, 32) In our experience, although amoxici-
llin efficiently covers the spectrum of aerobic bacteria such 
as Streptococcus viridans, it would not be appropriate to use 
it to cover other anaerobic bacteria or beta lactamase pro-
ducing dental pathogens (approximately 50% of anaerobic 
gram-negative bacteria isolated in the mouth produce beta 
lactamase). With regard to clindamycin, 10% of aerobic 
gram-positive bacteria (oral Streptococcus) are resistant to 
clindamycin, and 21% of anaerobic bacteria that we have 
isolated in cases of adult periodontitis are also resistant to 
this antibiotic. (31) 
6. ANTIMICROBIAL OPTIONS FOR PRO-
PHYLACTIC OR THERAPEUTIC PURPOSES
ß-lactamics: Penicillin G (parenteral), or phenoxymethyl-
penicillin (oral), continues to be one of the drugs of choice 
in dentistry and oral surgery because the majority of oral 
aerobic and anaerobic bacteria are sensitive to it. However, 
there are an increasing number of oral anaerobic bacteria 
that produce inactivant enzymes (ß-lactamases), making 
them resistant to penicillin, and leading to treatment fa-
ilure. (33, 34) Recently, we conducted a study to analyse 
261 aerobic and anaerobic bacteria isolated in 48 adult 
patients with periodontitis (31). We observed that 54.1% 
of bacteria of the Prevotella genus, 38.9% bacteria of the 
Fusobacterium genus, and 30% of the Capnocytophaga ge-
nus, produced ß-lactamase. For this reason, ß-lactamics that 
are capable of resisting the action of these enzymes, such as 
the amoxicillin + clavulanic acid association, have become 
the antibiotic of choice for oral infections. In our study, 
100% of the dental pathogenic strains (both aerobic and 
anaerobic) that were isolated in patients with periodontitis 
were sensitive to the amoxicillin + clavulanic acid associa-
tion. 100% of Streptococcus viridans were also sensitive to 
aminopenicillins. (31) 
Van Winkelhoff et al (35) reviewed subgingival bacterial 
microbiota susceptibility in adult patients with periodontitis 
in the Netherlands and Spain. They found significant di-
fferences between the levels of microbiota resistance in the 
two populations. A high level of resistance was found to 
penicillin, amoxicillin, clindamycin and particularly tetra-
cycline amongst the Spanish patients. In our experience, 22% 
of Streptococcus viridans and Prevotella spp, were resistant 
to tetracycline. (31) 
Metronidazole: In a recent study, Brescó et al (32) observed 
high resistance (50.5%) in bacteria isolated in patients with 
pericoronaritis and periapical lesions. We already know that 
aerobic gram-positive cocci such as S. viridans are usually 
resistant to this antimicrobial agent. In our series (31), 6% 
of bacteria of the Prevotella genus were also resistant. 
Macrolides: Macrolides are not considered as first line drugs 
in the treatment of dental infections. (36) Anaerobic dental 
pathogenic bacteria are resistant, and up to 47.7% of strep-
tococci isolated in our series were resistant to azithromycin. 
(31) Data from other studies indicate that in S. viridans, 
the high resistance to Macrolides (erythromycin and cla-
rythromycin) is often associated with a high resistance to 
tetracycline and clindamycin. (37) In Spain, Tomás I et al 
(38) demonstrated high prevalence of oral iatrogenic bac-
teraemia caused by streptococci resistant to erythromycin 
(40.8%) and clindamycin (21%), and the majority of bacteria 
isolated were sensitive to aminopenicillins. 
Clindamycin: Traditionally it has always been thought that 
very low concentrations of this antibiotic inhibit anaerobic 
bacteria growth. However, in our experience, up to 21.1% of 
Prevotella bacteria (the most commonly isolated anaerobic 
bacteria in the aforementioned study on adult periodontitis) 
(31) were resistant to clindamycin. Amongst the aerobic 
gram positive bacteria, it was observed that 10% of S. viri-
dans bacteria were resistant to clindamycin. (31)
7. EFFECTIVE/INEFFECTIVE COVER OF THE 
TARGET ORAL MICROBIOTA. CONSEQUEN-
CES
Pharmacodynamic cover is understood as the value of “the 
relation between serum pharmacokinetic parameters and 
in vitro susceptibility”, thus predicting efficacy in terms of 
a) the dose percentage interval at which levels that exceed 
the MIC (minimum inhibitory concentration for in vitro 
bacterial growth), must be over 40-50% for ß-lactamics, 
macrolides and lincosamides, and b) the relation of  the 
area under the curve of serum levels /CMI that must be 
over 25 for azalides (azythromycin). According to studies 
conducted on amoxicillin + clavulanic acid (39), spiramycin 
and metronidazole (49), antibiotic concentrations in gingival 
fluid are similar to or higher than serum levels. According to 
studies that have applied the concepts of pharmacokinetics 
and pharmacodynamics in dentistry, and analysed different 
antibiotics used for the five most prevalent bacteria isolated 
(but not all bacteria involved) in dental infections (Viridans 
group streptococci, Peptostreptococcus sp., Prevotella inter-
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media, Porphyromonas gingivalis and Fusobacterium nuclea-
tum) (41), the only antibiotics that meet pharmacodynamic 
requirements are amoxicillin + clavulanic acid, at a dose of 
875/125 mg / 8hrs, its new formulation of 2000/125 mg / 12 
hrs, and clindamycin 300 mg / 6-8hrs. However, clindamycin 
does not cover the following genera appropriately: Staphylo-
coccus, Streptococcus and Peptostreptococcus, because they 
present a notable level of resistance. (20) metronidazole, 
macrolides and spiramycin do not cover all gram positives 
(Streptococcus and Peptostreptococcus) and the latter two 
antibiotics do not cover Fusobacterium either. (41)
8. ANTIBIOTIC PROPHYLAXIS
8. 1. Which infectious complications need to be prevented?
There are four types of infections that need to be preven-
ted: 
a) local infections and their consequences (phlegmon, abs-
cess, tooth loss, loss of implants and prostheses). 
b) generalised systemic or local infections in patients with 
altered immune system response. 
c) systemic infections with a focal point of infection caused 
by a focal underlying condition in a patient who is suscep-
tible to infection (endocardial alterations, bone prostheses 
and joint replacements). 
d) vascular colonisations that induce lesions in susceptible 
patients. 
8. 2. Which patients and conditions require prophylaxis?
Non-invasive dental procedures do not normally require 
prophylaxis. In a healthy subject, the need for prophylaxis 
is based solely on the risk that the procedure entails (21); 
there is a high risk inherent to transplants, reimplants, grafts, 
tumour surgery and bone surgery (as in the case of ortho-
paedic and trauma surgery), as well as in periapical surgery, 
dental inclusions and possibly in root canal retreatment, 
where there may be previous infection. (20,21)
In patients at risk of systemic or local infection due to altered 
immune system response, antibiotic prophylaxis is indicated 
in intraligamental local anaesthesia, endodontic prosthetic 
care, curettage, drilling, tooth loss, transplants/reimplants, 
periapical surgery, periodontal surgery, bone surgery, frenec-
tomy, salivary gland biopsy and dental-facial orthopaedics, 
because they are all invasive procedures. (12)
In patients with risk factors for focal infection following 
bacteraemia (endocarditis, prosthetic infection), prophylaxis 
is always indicated for invasive procedures performed in 
these patients. (12) The French Agency for Health Product 
Health Safety advises against or contraindicates dental-
facial surgery, bone surgery, periodontal and periapical 
surgery, including root canal retreatment, root amputation, 
and reimplants in these patients, except under very specific 
circumstances, because there is such a high risk of infection. 
(20,21)
8.3. Which is the most appropriate prophylactic regimen for 
preventing the risk of bacteraemia?
As mentioned earlier, systemic infectious complications are 
usually mono-microbial and occur as a result of bacteria 
passing directly into the bloodstream and then spreading 
in the blood. Bacteraemia that occurs following an invasive 
oral procedure can significantly increase in the presence of 
periodontal disease. (42) This is due to the permeability of the 
epithelium that surrounds the tooth-tissue interface at a level 
of the prostaglandins in the local circulation that increase the 
number of leukocytes, and also because of fibrinogen levels, 
slowing down the circulation in both cases, and thus favouring 
the movement of bacteria into the bloodstream. (42) Thus, in 
animal models, endocarditis following bacteraemia occurred 
in 48% of rats with periodontal disease versus 6% in healthy 
rats. (43) In humans, the rate of bacteraemia following inva-
sive oral procedures varies according to cases, but different 
studies have reported rates of 51-88%. (4, 7-9) 
Distant infectious complications (systemic), are associated 
with aerobic bacteria, and oral viridans group streptococci 
in particular. They occur in patients with a susceptible site or 
with underlying disease. Thus, following dental procedures, 
bacteraemia caused by Streptococcus has been detected in 
75% of patients with periodontal disease and up to 30% of 
patients without the latter disease. (2,3) Bacteraemia caused 
by dental procedures is significantly associated with infective 
endocarditis. It is estimated that 14-20% of infective endo-
carditis cases are of an oral origin. (4, 44) 
What can be said of anaerobic bacteria detected on blood 
culture following dental procedures and oral surgery? What 
pathogenic role might long-term complications play, especia-
lly in patients with silent vascular lesions? Would prophylactic 
administration of amoxicillin or clindamycin be effective in 
avoiding these complications? What other antibiotics could 
cover the spectrum of dental pathogens in our setting? 
Rajasuo A et al (7) observed bacteraemia in 88% of patients 
who underwent tooth extraction, and 74% of these cases 
were caused by anaerobic bacteria (Prevotella, Eubacterium 
and Peptostreptococcus). Otten et al (8) observed bacteraemia 
following tooth extraction in 74% of patients studied, and 
35.8% of these were anaerobic bacteria alone. 
In view of all of this, if the objective of prophylaxis is to 
prevent all possible complications derived from bacteraemia, 
it seems clear that the ideal cover is achieved through high 
doses of amoxicillin/clavulanic acid, because of the signi-
ficantly frequent production of ß-lactamase in Prevotella, 
Fusobacterium and Capnocytophaga (31) and because of high 
resistance to tetracyclines (37) and azalides (azithromycin). 
(31). A problem may arise in patients who are allergic to 
ß-lactamics, where the choice of clindamycin appears to be 
the most logical, since S. viridans resistance is much higher in 
tetracyclines and macrolides, and macrolides are not active 
against Prevotella. Since bacteraemia is transient and short-
lived, prophylaxis should be administered 30 to 60 minutes 
before the dental procedure. A single dose is sufficient. 
8.4. Specific prophylaxis for infective endocarditis
As we have already seen, the incidence of transient bac-
teraemia has been widely studied, and stands at 60% and 
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88% following tooth extraction and periodontal surgery, 
respectively. (9, 22, 45) However, the pathogenic role of 
anaerobic periodontal pathogens and/or of the HACEK 
group in causing infective endocarditis is a completely di-
fferent question (12), while the presence of certain species 
in blood, fundamentally viridans group streptococci, has 
a much greater specific weight in this condition than in 
the overall incidence of bacteraemia. (45) This is why it 
has always been believed that streptococci should be the 
target in preventing infective endocarditis, and if  the latter 
occurs, it normally does so within two weeks of the dental 
procedure (22, 23) in risk patients. Antibiotic prophylaxis 
does not only act by killing bacteria, but also by inhibiting 
bacterial adherence. (46)
The risk can be calculated by multiplying harm by the 
probability of suffering such harm. In the case of infective 
endocarditis the risk is based on the catastrophic results it 
causes instead of its frequency, that varies from 1/115,500 
patients (47) to 1.5/100 in the case of patients with valve 
prostheses. (22) 
The risk depends on pre-existing cardiac factors and on the 
dental procedure. Logically, the risk of streptococcal viri-
dans bacteraemia is greater in certain invasive procedures 
such as those that involve the gingival sacs and in all oral sur-
gery (high-risk procedures). With regard to the endocarditis 
site, pre-existing cardiac disorders may be high-risk (valve 
prostheses, previous endocarditis, congenital cyanotic heart 
disease, or pulmonary shunts), or low-risk (mitral valve 
prolapse or regurgitation, aortic stenosis or regurgitation, 
tricuspid or pulmonary valve defects, ventricular septal 
defects, degenerative valve disease in the elderly). 
Prophylaxis is indicated in high-risk dental procedures in 
patients with pre-existing high-risk heart disorders. It is 
also recommendable, at the dentist’s discretion, in high-risk 
dental procedures in patients with pre-existing low-risk heart 
disorders, and in low-risk dental procedures in patients with 
pre-existing high-risk heart disorders. (12)
The standard recommended regimen (23) includes high 
doses of amoxicillin in children and adults alike, 1 hour 
prior to the dental procedure. The prophylactic regimen 
in adults should include 2g of  oral amoxicillin. (22) If  
findings in (mixed and solely anaerobic) bacteraemia of 
oral origin are heeded together with sensitivity data on 
dental pathogenic bacteria, we would suggest prophylactic 
administration of amoxicillin + clavulanic acid (2000/125), 
in order to afford the best cover against all potentially pa-
thogenic bacteria that reach the bloodstream. This would 
ensure simultaneous eradication of aerobic and anaerobic 
bacteria that are susceptible of causing complications, and 
of secondary colonisation of dental pathogenic bacteria in 
vascular lesions. 
Prophylaxis should be administered as a single dose except 
in cases where the procedure takes more than 2 hours, in 
which case another dose should be administered. Clindamy-
cin or clarythromycin is recommended in patients who are 
allergic to ß-lactamics. (22) As mentioned earlier with regard 
to prevention of bacteraemia, macrolides and azalides do 
not appear to be appropriate in Spain because of the high 
rate of resistance shown by viridans group streptococci. 
Furthermore, patients with congenital heart disease are 
usually carriers of resistant micro-organisms, and this may 
cause prophylactic failure if  the most appropriate antibiotic 
is not chosen. (48) 
8.5. Specific prophylaxis against local infection
With regard to indications for prophylaxis against local 
infection, in the case of both healthy subjects and patients 
with altered immune system response as described ear-
lier, the prophylactic regimen should cover the habitual 
microbiota as well as periodontic pathogens in view of the 
high prevalence of periodontitis in the population. Bearing 
in mind the resistance phenotypes discussed earlier (inclu-
ding ß-lactamase production on the part of the habitual 
anaerobic microbiota and of  certain dental pathogens), 
and the pharmacodynamic cover required, it appears to be 
advisable to use high doses of amoxicillin together with a 
ß-lactamase inhibitor, such as clavulanic acid. 
In certain circumstances, there is a problem in distinguishing 
between the term “prophylaxis” and the term “preventive 
treatment” regarding infection arising from surgery. In the 
study conducted in Spain, it was demonstrated that compli-
cations following third molar extraction included infective 
disease, and not just inflammatory disease, since significant 
differences were found in the frequency of infectious com-
plications between groups receiving amoxicillin/clavulanic 
acid 2000/125mg as treatment (5 days), pre-operative pro-
phylaxis (single dose) and placebo (2.7%, 5.3% and 16% 
respectively). (49) The rate of infectious complications was 
higher in the case of osteotomy or longer surgery, and in 
these cases treatment was clearly more effective than pro-
phylaxis or placebo. (49) Only amoxicillin/clavulanic acid at 
a suitable dose and interval covers treatment requirements, 
followed by clindamycin, which starts to present problems 
in the case of streptococci, peptostreptococci and anaerobic 
gram-negative dental pathogenic bacteria. 
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